| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5968979 | HORIZON THERAP US | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9999608 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US9561197 | HORIZON THERAP US | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Sep, 2030
(6 years from now) | |
| US8642012 | HORIZON THERAP US | Methods of treatment using ammonia-scavenging drugs |
Sep, 2030
(6 years from now) | |
| US9962359 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10045959 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10183005 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10045958 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10183006 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10668040 | HORIZON THERAP US | Treatment of urea cycle disorders in neonates and infants |
Sep, 2030
(6 years from now) | |
| US10183003 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10183002 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US10183004 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Sep, 2030
(6 years from now) | |
| US9326966 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| US9095559 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| US9254278 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| US8404215 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging |
Mar, 2032
(7 years from now) | |
Ravicti is owned by Horizon Therap Us.
Ravicti contains Glycerol Phenylbutyrate.
Ravicti has a total of 17 drug patents out of which 1 drug patent has expired.
Expired drug patents of Ravicti are:
- US5968979
Ravicti was authorised for market use on 01 February, 2013.
Ravicti is available in liquid;oral dosage forms.
Ravicti can be used as treatment of a nitrogen metabolism disorder, treatment of a urea cycle disorder, dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder.
The generics of Ravicti are possible to be released after 09 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-157) | Apr 28, 2024 |
| New Patient Population(NPP) | Dec 21, 2021 |
| Orphan Drug Exclusivity(ODE-42) | Feb 01, 2020 |
| NE(NE) | Feb 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Feb 01, 2020 |
Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder; Treatment of a nitrogen metabolism disorder
Dosage: LIQUID;ORAL
RAVICTI family patents
